PD-1 develops bullous pemphigoid after treatment of follicular lymphoma: a case report and literature review
-
-
Key words:
- PD-1 /
- bullous pemphigoid /
- lymphoma
-
-
[1] 秦燕, 赵凤仪, 周钰, 等. 程序性死亡受体1抑制剂联合利妥昔单抗方案治疗复发难治弥漫大B细胞淋巴瘤疗效和安全性的初步分析[J]. 中华肿瘤杂志, 2020, 42(12): 1034-1039. doi: 10.3760/cma.j.cn112152-20200506-00410
[2] Armand P, Janssens A, Gritti G, et al. Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma[J]. Blood, 2021, 137(5): 637-645. doi: 10.1182/blood.2019004753
[3] Salati M, Pifferi M, Baldessari C, et al. Stevens-Johnson syndrome during nivolumab treatment of NSCLC[J]. Ann Oncol, 2018, 29(1): 283-284. doi: 10.1093/annonc/mdx640
[4] 马慧淼, 陈媚, 刘猛, 等. 纳武单抗导致Stevens-Johnson综合征1例[J]. 中国肿瘤临床, 2020, 47(2): 105-106. doi: 10.3969/j.issn.1000-8179.2020.02.449
[5] 赵静, 苏春霞. 《CSCO免疫检查点抑制剂相关的毒性管理指南》解读: 对比NCCN免疫治疗相关毒性管理指南[J]. 实用肿瘤杂志, 2020, 35(1): 11-15. https://www.cnki.com.cn/Article/CJFDTOTAL-SYZZ202001002.htm
[6] 王媛, 冯素英. 药物诱发大疱性类天疱疮的研究进展[J]. 中华皮肤科杂志, 2020, 53(6): 487-489.
[7] Schaberg KB, Novoa RA, Wakelee HA, et al. Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy[J]. J Cutan Pathol, 2016, 43(4): 339-346. doi: 10.1111/cup.12666
[8] Siegel J, Totonchy M, Damsky W, et al. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy[J]. J Am Acad Dermatol, 2018, 79(6): 1081-1088. doi: 10.1016/j.jaad.2018.07.008
[9] Lopez AT, Khanna T, Antonov N, et al. A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors[J]. Int J Dermatol, 2018, 57(6): 664-669. doi: 10.1111/ijd.13984
[10] Naidoo J, Schindler K, Querfeld C, et al. Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1[J]. Cancer Immunol Res, 2016, 4(5): 383-389. doi: 10.1158/2326-6066.CIR-15-0123
[11] Riveiro-Barciela M, Trallero-Araguás E, Martínez-Valle F, et al. Toxicities from immunotherapy: From clinical trials to real-world clinical practice[J]. Med Clin(Barc), 2020, 155(12): 541-547.
[12] Rofe O, Bar-Sela G, Keidar Z, et al. Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression[J]. Clin Exp Dermatol, 2017, 42(3): 309-312. doi: 10.1111/ced.13042
[13] Horvat TZ, Adel NG, Dang TO, et al. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center[J]. J Clin Oncol, 2015, 33(28): 3193-3198. doi: 10.1200/JCO.2015.60.8448
[14] Esfahani K, Miller WH Jr. Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade[J]. N Engl J Med, 2017, 376(20): 1989-1991. doi: 10.1056/NEJMc1703047
-
下载:
图(9)
计量
- 文章访问数: 952
- PDF下载数: 649
- 施引文献: 0